98%
921
2 minutes
20
Background: Anemia is a significant global health issue affecting approximately one-third of the world's population. Non-communicable diseases (NCDs) such as diabetes, cardiovascular diseases, and chronic kidney disease are increasingly recognized as significant contributors to anemia, particularly in populations with high prevalence of these conditions.
Methods And Results: Globally, the prevalence of anemia caused by NCDs has increased significantly from 249.1 million to 368.4 million, representing a 48% increase since 1990. A similar trend can be observed in YLDs. The burden was expected to continue to grow in the next 20 years. The curves of anemia-related burden showed an intersection for different genders around the age of children under five and women of reproductive age, beyond which women exhibit a higher burden of anemia, compared to men. Populous countries like India [102.35 million (95% UI: 97.49-108.13)], and China [45.63 million (95% UI: 42.15-49.89)] have the largest number of anemia cases caused by NCDs. Hemoglobinopathies and hemolytic anemias, being the key underlying cause of anemia, accounted for 69.0% of the anemia-related burden. There is a discernible upward trend across all socio-demographic index (SDI) groups over the years, particularly in low-middle SDI countries. While age-standardized, the burden of anemia in all SDI groups has shown a decrease trend. And the highest prevalence rates and YLDs rates always appeared in low-middle and middle SDI regions, similar with that of health system grouping levels.
Conclusion And Interpretation: Our study reveals that anemia is particularly prevalent in low- and middle-income countries, where it significantly impacts vulnerable populations such as children under five and women of reproductive age. Understanding these multifaceted influences is essential for developing targeted and effective strategies to alleviate the burden of anemia globally.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12364641 | PMC |
http://dx.doi.org/10.3389/fnut.2025.1557986 | DOI Listing |
PLoS Comput Biol
September 2025
Department of Genome Sciences, University of Washington, Seattle, Washington, United States of America.
Fanconi Anemia (FA) is a heritable syndrome characterized by DNA damage repair deficits, frequent malformations and a significantly elevated risk of bone marrow failure, leukemia, and mucosal head and neck squamous cell carcinomas (HNSCC). Hematopoietic stem cell gene therapy can prevent marrow failure and lower leukemia risk, but mucosal gene therapy to lower HNSCC risk remains untested. Major knowledge gaps include an incomplete understanding of how rapidly gene-corrected cellular lineages could spread through the oral epithelium, and which delivery parameters are critical for ensuring efficient gene correction.
View Article and Find Full Text PDFCurr Atheroscler Rep
September 2025
Division of Gastroenterology and Hepatology, Lynda K. and David M. Underwood Center for Digestive Health, Houston Methodist Hospital, Houston, TX, USA.
Purpose Of Review: This review aims to characterize the known cardiovascular (CV) manifestations associated with inflammatory bowel disease (IBD) and the underlying mechanisms driving these associations.
Recent Findings: Gut dysbiosis, a hallmark of patients with IBD, can result in both local and systemic inflammation, thereby potentially increasing the risk of cardiovascular disease (CVD) in the IBD population. Micronutrient deficiencies, anemia, and sarcopenia independently increase the risk of CVD and are frequent comorbidities of patients with IBD.
AJP Rep
July 2025
Allo Hope Foundation, Tuscaloosa, Alabama.
Objective: The purpose of this study was to investigate mental health and impacts upon daily life in patients with a history of pregnancy alloimmunization, and secondarily to examine the relationship between disease severity and quality of care on these outcomes.
Study Design: This was a survey administered between November 2022 and February 2023 to U.S.
Am J Hematol
September 2025
Australian Centre for Blood Diseases Monash University, Melbourne, Australia.
Multiple myeloma (MM) is an incurable blood cancer characterized by clonal bone marrow plasmacytosis, hypercalcemia, renal failure, anemia, and osteolytic bone disease. Approximately 20% of NDMM patients, not predicted to have high-risk disease at diagnosis, progress early, despite optimal induction +/- ASCT and lenalidomide maintenance, and are subsequently categorized as functional high-risk (FHR) disease. Standardized risk-stratification models incorporate biomarkers of tumor burden, existence of high-risk cytogenetics, with the presence/absence of plasma cell leukemia/extramedullary disease to attribute high-risk at diagnosis; however, depth/duration of response to novel agent-based induction (NA-IND) as dynamic markers of disease risk have not been defined.
View Article and Find Full Text PDFPLoS One
September 2025
Department of Internal Medicine, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
In resource-limited settings in Africa, which harbour the greatest burden of Sickle Cell Disease (SCD) globally, poor care outcomes are driven in part, by a lack of trained healthcare providers (HCP) and an absence of context-specific treatment guidelines appropriate to the level of healthcare facility. The study aimed to evaluate the impact of a structured training program on HCP's knowledge of SCD in Ghana. This was prospective cross-sectional study involving HCPs from 46 health facilities from 4 out of 16 regions in Ghana.
View Article and Find Full Text PDF